

1 **Identification of Genetic Loci Simultaneously Associated with Multiple Cardiometabolic**
2 **Traits**

3 Alexis C. Wood, Ph.D.¹, Amit Arora MPH², Michelle Newell MS², Victoria L. Bland PhD³, Jin
4 Zhou PhD⁴, Nicola Pirastu, PhD⁵, Jose M. Ordovas, Ph.D^{6,7}, Yann C. Klimentidis, Ph.D^{2,8}

5
6 ¹USDA/ARS Children’s Nutrition Research Center, 1100 Bates Avenue, Houston, TX

7 ²Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public
8 Health, University of Arizona, Tucson, AZ

9 ³Division of Geriatric Medicine, School of Medicine, University of Colorado Anschutz Medical
10 Campus, Aurora, CO

11 ⁴Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA

12 ⁵Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh,
13 Scotland

14 ⁶Nutrition and Genomics Laboratory, Jean Mayer U.S. Department of Agriculture Human
15 Nutrition Research Center on Aging, Tufts University, Boston, MA

16 ⁷IMDEA-Food, Madrid, Spain

17 ⁸BIO5 Institute, University of Arizona, Tucson, AZ

18

19 Corresponding author: Alexis C. Wood, USDA/ARS Children’s Nutrition Research Center - Rm

20 2036, 1100 Bates Avenue, Houston, TX 77030. Tel: 713-798-7055. Email:

21 LekkiWood@Gmail.com

22

23 Word count: 2,706

24 Short title: GWAS of Cardiometabolic Traits

25 Subject terms: GWAS, Cardiometabolic Disease, Epidemiology, Risk Factors, Pleiotropy

26 **Sources of Support**

27 The authors would like to acknowledge support from the National Heart, Lung, and Blood

28 Institutes (R01-HL136528). Dr. Wood's role on this project was funded, in part, by USDA/ARS

29 cooperative agreement # 58-3092-5-001. The contents of this publication do not necessarily

30 reflect the views or policies of the U.S. Department of Agriculture, nor does mention of trade

31 names, commercial products, or organizations imply endorsement by the U.S. Government. The

32 funders had no role in study design, data collection and analysis, decision to publish, or

33 preparation of the manuscript.

34

35

36

37

38 **Abbreviations:**

39 ALT: alanine aminotransferase

40 BMI: body mass index

41 CARDIOGRAM: Coronary Artery Disease Genome-wide Replication And Meta-analysis

42 CAD: coronary artery disease

43 CMD: cardiometabolic disorders

44 CVD: cardiovascular disease

45 DIAGRAM: Diabetes Genetics Replication And Meta-analysis

46 DBP: diastolic blood pressure

47 GERA: Genetic Epidemiology Research on Adult Health and Aging cohort

48 GIANT: Genetic Investigation of Anthropometric Traits consortium

49 GLGC: Global Lipids Genetics Consortium

50 GWAS: genome-wide association studies

51 HbA1c: hemoglobin A1c

52 HDL-C: high-density lipoprotein cholesterol

53 LDL-C: low-density lipoprotein cholesterol

54 NHANES: National Health and Nutrition Examination Survey

55 PPFC: posterior probability of full colocalization

56 SBP: systolic blood pressure

57 T2D: type 2 diabetes

58 TGs: triglycerides

59 UK: United Kingdom

60 WHR: waist-to-hip-ratio

61 WHRadjBMI: waist-to-hip ratio adjusted for BMI

62 **Abstract**

63 **Background and Aims:** Cardiometabolic disorders (CMD) arise from a constellation of features
64 such as increased adiposity, hyperlipidemia, hypertension and compromised glucose control.
65 Many genetic loci have shown associations with individual CMD-related traits, but no
66 investigations have focused on simultaneously identifying loci showing associations across all
67 domains. We therefore sought to identify loci associated with risk across seven continuous
68 CMD-related traits.

69 **Methods and Results:** We conducted separate genome-wide association studies (GWAS) for
70 systolic and diastolic blood pressure (SBP/DBP), hemoglobin A1c (HbA1c), low- and high-
71 density lipoprotein cholesterol (LDL-C/HDL-C), waist-to-hip-ratio (WHR), and triglycerides
72 (TGs) in the UK Biobank (N=356,574–456,823). Multiple loci reached genome-wide levels of
73 significance (N=145-333) for each trait, but only four loci (in/near *VEGFA*, *GRB14-COBL1*,
74 *KLF14*, and *RGS19-OPRL1*) were associated with risk across all seven traits ($P < 5 \times 10^{-8}$). We
75 sought replication of these four loci in an independent set of seven trait-specific GWAS meta-
76 analyses. *GRB14-COBL1* showed the most consistent replication, revealing nominally
77 significant associations ($P < 0.05$) with all traits except DBP.

78 **Conclusions:** Our analyses suggest that very few loci are associated in the same direction of risk
79 with traits representing the full spectrum of CMD features. We identified four such loci, and an
80 understanding of the pathways between these loci and CMD risk may eventually identify factors
81 that can be used to identify pathologic disturbances that represent broadly beneficial therapeutic
82 targets.

83

84 *Key words:* GWAS, cardiometabolic disease, pleiotropy, risk alleles, fat distribution

85 **Introduction**

86 Cardiometabolic risk, the chance of developing type 2 diabetes (T2D), cardiovascular disease
87 (CVD) and/or stroke, is typically assessed through measures of adiposity, glucose control, lipid
88 metabolism, and blood pressure [1]. The clustering of these risk factors has been termed CMD
89 and is defined by The American College of Cardiology as the presence of hypertension, poor
90 glucose control, dyslipidemia, and abdominal obesity [2]. Recent data from the National Health
91 and Nutrition Examination Survey (NHANES) indicate that among US adults, almost 90% of
92 those with obesity, 50% with overweight and 25% of those at a normal weight met criteria for
93 elevated risk in at least of these indicators [3]. While individual measures of cardiometabolic risk
94 are linked with the development of CVD and T2D, studies are not unified in identifying which
95 specific measures convey the greatest risk for these outcomes [4, 5]. Where evidence does
96 strongly converge is in showing that the number of cardiometabolic risk factors is directly
97 proportional to the risk of developing endpoints such as T2D, CVD, and for predicting mortality
98 [6].

99 Each CMD feature results from a complex interplay between host genetics and lifestyle
100 factors. Health behaviors such as physical activity and good dietary habits are associated with
101 protection across multiple cardiometabolic risk factors [7], suggesting at least a partially shared
102 behavioral etiology underlying CMD traits. However, the role that genetics plays in any shared
103 etiology between CMD traits is not well understood[8, 9]. For example, only two loci have
104 previously been identified as being implicated across T2D and cardiovascular disease:
105 *CDKN2A/B* and *IRSI*[9, 10]. Identifying those genetic factors that convey risk across multiple
106 CMD traits may increase our understanding of why risk factor clustering is not uniform across
107 individuals, and further help identify those whose overall CMD profile suggests a greater risk of

108 T2D and CVD and whom may especially benefit from behavioral interventions [11]. All CMD
109 indicators show significant heritability [12, 13], with modest genetic correlations in the range of
110 .1 -.5, suggesting both shared and measure-specific genetic loci across all traits associated with
111 CMD [14, 15]. In addition, a small number of loci have been identified that increase the risk for
112 one indicator (e.g., low-density lipoprotein cholesterol) but decrease the risk for another (e.g.,
113 glucose control [16-19]), mirroring some of the therapeutic effects of statins which reduce
114 dyslipidemia but convey a slightly increased risk for T2D [20-22]. However, we are not aware of
115 any studies that seek to identify variants associated with all the cardiometabolic risk factors
116 forming the features of CMD. The identification of such loci, if they exist, may help identify
117 underlying etiological pathways shared across many risk factors, improve our risk stratification
118 efforts and provide information on targets for therapeutics which, by seeking to address multiple
119 CMD risk factors, may have a broader range of beneficial clinical changes [23-25].

120 The present study aims to identify loci that are associated with each of seven
121 cardiometabolic traits, representing the four features of CMD, in the same (risk predisposing)
122 direction. Using data from the UK Biobank, which allowed us to leverage large numbers of
123 individuals with both genetic data and phenotype data across multiple indicators of
124 cardiometabolic disease, we took a genome-wide approach to identify variants significantly
125 associated with each of glucose control, central adiposity, and multiple measures of lipid
126 metabolism, and blood pressure. We then validated any significant associations in the published
127 summary statistics from independent large-scale meta-analytic GWAS for each trait.

128

129

130

131

132 **Methods**

133 *Study Population*

134 The UK Biobank is a multi-center prospective cohort study of 500,000 adults ages 39 to
135 72 living in the UK. At each one of the 21 assessment centers, participants answered
136 questionnaires, were interviewed, and were physically measured as part of a baseline visit that
137 occurred between 2006 and 2010. A blood draw in a non-fasting state was performed for
138 subsequent genetic and biomarker analysis. Among the biomarkers tested were directly-
139 measured circulating LDL-C, HDL-C, hemoglobin A1c (HbA1c), TG, and alanine
140 aminotransferase (ALT). The UK Biobank was approved by the National Information
141 Governance Board for Health and Social Care and the National Health Service North West
142 Multicentre Research Ethics Committee. All participants provided informed consent. Prevalent
143 T2D was defined according to the following criteria: 1) self-reported T2D or generic diabetes in
144 verbal interviews, 2) over the age of 35 years at diagnosis, and 3) not using insulin within one
145 year of diagnosis, to exclude possible type-1 diabetes cases [26].

146

147 *Genotype data*

148 DNA of participants was genotyped with the Affymetrix UK Biobank Axiom Array
149 (Santa Clara, CA, USA), except for 10% of participants genotyped with the Affymetrix UK
150 BiLEVE Axiom Array. Information about genotype imputation, principal components analysis,
151 and quality control procedures can be found elsewhere [27]. Briefly, individuals were excluded if
152 they exhibited unusually high heterozygosity, a high missing rate (>5%), or exhibited a
153 mismatch between genetically inferred sex and self-reported sex. SNPs were excluded from

154 analyses based on Hardy Weinberg equilibrium ($p < 1 \times 10^{-6}$), high missing rate ($> 1.5\%$), low
155 minor allele frequency ($< 0.1\%$), or a low imputation accuracy ($info < 0.4$).

156

157 *GWAS and Genetic Correlations of Trait Measures*

158 We first examined seven continuous cardiometabolic traits in the UK Biobank: HbA1c,
159 LDL-C, HDL-C, TGs, waist-to-hip ratio adjusted for BMI (WHRadjBMI), and SBP and DBP
160 adjusted for BMI. Although fasting glucose is a commonly used glycemic trait, since UKB
161 participants are not fasted at the time of blood draw, we chose to use HbA1c instead. This allows
162 us to achieve a similar sample size and power for each of the seven traits in the discovery
163 analysis. Although HbA1c does have some limitations, is it more stable and reflective of long-
164 term glycemia than fasting glucose. For the analyses of TG and HDL-C, we excluded individuals
165 reporting cholesterol-lowering medications. For the analysis of LDL-C, we adjusted the values of
166 people reporting cholesterol-lowering medication, by dividing their LDL-C values by a
167 correction factor of 0.63. For the analysis of HbA1c, we excluded individuals with prevalent
168 T2D (see above). For the analyses of SBP and DBP, we obtained the mean values across two
169 manual measurements and adjusted for the effect of anti-hypertensive medications by adding 15
170 and 10 points to SBP and DBP, respectively, among individuals reported to be on anti-
171 hypertensive medications (and an additional 2 measurements in a subset of individuals) [28]. We
172 used LD-score regression to estimate genetic correlations across all pairs of trait [29].

173

174 *GWAS Replication Associations*

175 We replicated identified associations by examining summary statistics of previously
176 conducted large-scale GWAS of the same traits: LDL-C, HDL-C, and TG from the Global Lipids

177 Genetics Consortium (GLGC; n=188,577)[30], WHRadjBMI from the Genetic Investigation of
178 Anthropometric Traits (GIANT) consortium (n=224,459) [31], SBP and DBP from Genetic
179 Epidemiology Research on Adult Health and Aging (GERA) cohort (n=99,785) [32], and HbA1c
180 from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC; n= 123,665)
181 [33].

182

183 *Follow-up associations with CMD end points*

184 We examined the association of the four identified SNPs with coronary artery disease
185 (CAD), T2D, and stroke, some of the major outcomes arising from CMD, using GWAS meta-
186 analysis results published by the Coronary Artery Disease Genome-wide Replication And Meta-
187 analysis (CARDIOGRAM; n= up to 185,000)[34], Diabetes Genetics Replication And Meta-
188 analysis (DIAGRAM; n= 898,130)[34], and MEGASTROKE (n= 521612) [35] consortia.

189

190 *Statistical analysis*

191 All UK Biobank phenotypes were inverse-normalized prior to GWAS. Although this
192 limits our ability to interpret effect sizes, it does allow us to both normalize the variables and to
193 compare effect sizes across traits. GWAS was performed with BOLT-LMM software which
194 implements a linear mixed model regression that includes a random effect consisting of all SNP
195 genotypes other than the one being tested.[36] We included the following variables as covariates:
196 age, age², sex, center, genotyping chip, and the first 10 principal components. SNPs were
197 selected if their beta coefficient had the same direction of effect (opposite direction for HDL-C)
198 and a corresponding p-value < 5×10^{-8} for each of the seven traits. If several SNPs were within a
199 1 Mb region, we chose the one with the lowest p-value based on a multivariate analysis

200 conducted with metaCCA [37]. We also performed multiple-trait genetic colocalization using
201 the “*hyprcoloc*” package in R to identify the best candidate variant given a genomic region for
202 each locus, using a region \pm 250kb region around the lead SNP.[38] A posterior probability of
203 full colocalization (PPFC) threshold of 0.72 (e.g. alignment probability=0.85 and regional
204 probability=0.85) was considered. In the replication dataset, we examined SNPs identified in the
205 UK Biobank discovery set, and considered that a consistent direction of effect, and with $p < 0.05$,
206 qualified as a replication, given the smaller sample sizes in the replication datasets.

207

208 **Results**

209 *UK Biobank GWAS*

210 Phenotypic and genetic correlations among seven traits are shown in **Supplementary**
211 **Figure 1**. Both phenotypic and genetic correlations were generally weak, with the exception of
212 some correlations among some lipid traits and between SBP and DBP. In GWAS among UK
213 Biobank participants, we identified 16 SNPs at four loci associated at genome-wide significance
214 with each of seven quantitative traits in the same risk-conferring/protecting direction, in/near
215 *VEGFA*, *GRB14-COBL1*, *KLF14*, and *RGS19-OPRL1* (**Table 1 and Figure 1**). In sex-stratified
216 analyses, there were no genome-wide significant SNPs for each trait (**Figure 1, Supplementary**
217 **Table 1**). Colocalization analyses showed colocalization across all seven traits for the *GRB14-*
218 *COBL1* locus, across six traits for *KLF14* and *RGS19-OPRL1*, and across five traits for *VEGFA*
219 (all PPFC > 0.72; **Supplementary Table 2**).

220

221 *GWAS in replication samples*

222 Among the four SNPs identified in UK Biobank, we found that all four exhibit the same
223 direction of risk effect across all seven traits, but do not reach $p < 0.05$ across all traits, likely due
224 to the substantially smaller sample sizes in those studies as compared to the UK Biobank (**Table**
225 **2**).

226

227 *Follow-up associations with CMD end points and phenome-wide association study*

228 We found directionally consistent associations of the four loci identified in UK Biobank
229 with T2D, CAD, and stroke, although not all associations achieved statistical significance,
230 particularly for stroke (**Supplementary Table 3**). In silico phenome-wide association analyses
231 (PheWAS) of these four loci revealed associations with fat distribution patterns and
232 cardiometabolic conditions and medications, with limited to no evidence of adverse associations
233 with other conditions (see **Supplementary Tables 4-8**).

234

235 **Discussion**

236 This is the first study, of which we are aware, to take a broad and well-powered genome-
237 wide approach to simultaneously identifying genetic loci associated with seven cardiometabolic
238 risk factors representing the four domains of CMD. We observed only four loci that increase the
239 risk for all seven of our traits; raised TGs and LDL-C, lowered HDL-C, raised HbA1c, and
240 systolic and diastolic blood pressure. Given that multiple robust genetic associations have been
241 published for each of our seven traits individually, these findings suggest that loci which
242 influence all seven features CMD are less common, and much of the genetic etiology is trait-
243 specific.

244 We found four loci which simultaneously associated with risk across seven CMD traits at
245 genome-wide levels of significance. Although this is the first study, of which we are aware to
246 conduct discovery across all seven traits simultaneously, previous studies have identified
247 associations between loci in *GRB14-COBLL1*, and *RGS19-OPRL1* with each of our
248 cardiometabolic traits independently. The intergenic SNP rs13889216 in *GRB14-COBLL1* , or
249 the nearby SNP rs10195252 in *GRB14* have previously been associated at genome-wide levels of
250 significance with WHR ratio (sometimes with a larger effect size in females) [31, 39, 40] and
251 levels of TGs [40-43], HDL-C [31, 40, 42-44] and LDL-C [31]. Other studies have associated
252 these SNPs with additional traits often used as indicators of cardiometabolic disease or
253 cardiometabolic disease risk, such as total cholesterol [43], T2D [31, 43, 45] and other indices of
254 glycemic control [31, 40, 41, 43], often at levels approaching genome-wide significance.
255 Similarly, rs8126001 found in the 5' UTR of *OPRL1* and 2kb upstream from *RGS19* has been
256 previously associated with TG levels [42], HDL-C [42], SBP[46] and WHRadjBMI as well as
257 waist circumference in UK Biobank [46, 47], although its most replicated associations to date
258 have been with alcohol use/abuse. Similarly, associations have been observed between variants
259 at *KLF14* and *VEGFA* with both T2D [48] and HDL-C levels in large-scale GWAS [49]. Taken
260 together, these previous data suggest our analysis approach is robust, and supporting the notion
261 that our associations of each of these four loci with all seven traits is generalizable. In the light of
262 evidence showing that the number of cardiometabolic risk factors is directly proportional to the
263 risk of T2D, CVD and mortality [6], information that these loci associate with risk across
264 multiple traits could be seen to raise the importance of these loci to the risk of developing these
265 conditions when compared to loci which raise the risk profile of a fewer number of traits.

266 Understanding the mechanisms that link our four loci to CMD risk may yield insights
267 into the full clinical profile of CMD. In the broader literature, two of our loci show multiple
268 associations with mechanisms underlying, and/or patterns of, fat deposition. For example,
269 *KLF14* regulates the expression of several genes in adipose tissue, and has been associated with
270 favorable adiposity [50], and, in women with adipogenesis, shifts in central vs. gynoid adiposity,
271 and the shift in the number and size of adipocytes [51]. In turn, *GRB14* and the *GRB14-COBLL1*
272 locus have both been associated with body fat distribution (reviewed in [52]), and variation in or
273 near *GRB14-COBLL1* to alter gene expression in subcutaneous fat, and in omental but not
274 mesenteric visceral fat [53]. These findings suggest that at least some of our putative loci are
275 united by their associations with patterns of fat deposition – an unsurprising implication given
276 that fat deposition patterning has recently emerged as a stronger indicator of cardiometabolic risk
277 factor clustering than overall adiposity, particularly in women (e.g. [54, 55]). In both genders,
278 visceral fat is an indicator of increased cardiometabolic risk [54, 56-62], however in women
279 only, deposition of fat in the lower body (gluteal-femoral fat) is associated with protection from
280 CMD risk factors [59, 63] and their downstream endpoint of CVD [55]. Supporting the notion
281 that CMD risk alleles may operate through fat patterning, a genetic risk score associated with fat
282 deposition phenotypes such as WHR, gluteofemoral fat and abdominal fat volume, also
283 associated CMD traits, as well as T2D and CVD [64], and the protective associations of *GRB14-*
284 *COBLL1* variants on adverse lipid profiles have been theorized to be mediated through
285 alterations in body fat distribution [52].

286 There are of course limitations to our findings. Our sample is comprised of individuals
287 with European-ancestry and generalizations beyond this population are not advised. In addition,
288 while the rationale for the current analyses was to identify loci which most increase the risk of

289 cardiometabolic disease by exerting effects across multiple risk indicators simultaneously, our
290 loci have not been widely associated with hard outcomes such as CVD, except for associations of
291 *GRB14-COBLL1*, *KLF14*, and *VEGFA* with T2D (**Supplementary Table 4**) [31, 43, 45].
292 Finally, many of our loci have been observed to have sex-specific effects especially with regards
293 to associations with fat patterning [51, 53, 65], and our analyses suggested sex-specific
294 magnitudes of associations with the our seven CMD traits, we were not powered to detect these
295 through formal interaction analyses. Future research should address these limitations, and also
296 continue to examine the excess of risk associated with visceral fat and identify mechanisms
297 linking fat deposition and cardiometabolic risk.

298 These current findings suggest that from all loci known to affect CMD related traits, only
299 a few may have effects across multiple traits, which are strong enough to be readily detectable at
300 genome-wide levels of significance. Although the effect sizes of these naturally occurring
301 genetic variants are very small, they do not necessarily reflect the importance of the pathways
302 that they point to. Interventions may thus have a much larger, more clinically meaningful impact
303 than immediately apparent from the effect sizes of the SNP-risk factor associations used to
304 identify these pathways. This has been illustrated in the case of *HMGCR* and statins with LDL-C
305 [66, 67]. If these loci serve as an indicator of risk across the highest number of CMD features,
306 and if future research identifies pathways linking these loci to CMD, such as via changes in fat
307 patterning, this research may eventually give insights into therapeutic targets that will yield a
308 broader range of clinical improvement.

309

310 **Acknowledgments**

311 This research was conducted using the UK Biobank Resource under Application Number 15678.

312 We thank the participants and organizers of the UK Biobank. The authors would also like to

313 acknowledge the vital contributions of the GWAS consortia: GLGC, MAGIC, GIANT,

314 DIAGRAM, CARDIOGRAM, as well as all organizers and participants of individual

315 participating studies.

316

317 **Disclosures**

318 The authors have no relevant conflicts of interest to disclose.

319

320

References

- 321
322
323 [1] Sasson C, Eckel R, Alger H, Bozkurt B, Carson A, Daviglius M, et al. American Heart
324 Association Diabetes and Cardiometabolic Health Summit: Summary and Recommendations. J
325 Am Heart Assoc. 2018;7:e009271.
- 326 [2] Cardiology ACo. Cardiometabolic Initiatives. 2020.
- 327 [3] Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The
328 obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic
329 risk factor clustering: prevalence and correlates of 2 phenotypes among the US population
330 (NHANES 1999-2004). Archives of internal medicine. 2008;168:1617-24.
- 331 [4] Saydah S, Bullard KM, Imperatore G, Geiss L, Gregg EW. Cardiometabolic risk factors
332 among US adolescents and young adults and risk of early mortality. Pediatrics. 2013;131:e679-
333 e86.
- 334 [5] Danaei G, Lu Y, Singh GM, Carnahan E, Stevens GA, Cowan MJ, et al. Cardiovascular
335 disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors
336 from 1980 to 2010: a comparative risk assessment. Lancet Diabetes & Endocrinology. 2014.
- 337 [6] Reddigan JI, Ardern CI, Riddell MC, Kuk JL. Relation of physical activity to cardiovascular
338 disease mortality and the influence of cardiometabolic risk factors. Am J Cardiol.
339 2011;108:1426-31.
- 340 [7] Waxman A, World Health A. WHO global strategy on diet, physical activity and health.
341 Food Nutr Bull. 2004;25:292-302.
- 342 [8] Fernandes Silva L, Vangipurapu J, Laakso M. The "Common Soil Hypothesis" Revisited-
343 Risk Factors for Type 2 Diabetes and Cardiovascular Disease. Metabolites. 2021;11.

- 344 [9] Strawbridge RJ, van Zuydam NR. Shared Genetic Contribution of Type 2 Diabetes and
345 Cardiovascular Disease: Implications for Prognosis and Treatment. *Curr Diab Rep.* 2018;18:59.
- 346 [10] Zhao W, Rasheed A, Tikkanen E, Lee JJ, Butterworth AS, Howson JMM, et al.
347 Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with
348 coronary heart disease. *Nat Genet.* 2017;49:1450-7.
- 349 [11] Joseph PG, Pare G, Anand SS. Exploring gene-environment relationships in cardiovascular
350 disease. *Can J Cardiol.* 2013;29:37-45.
- 351 [12] Vattikuti S, Guo J, Chow CC. Heritability and genetic correlations explained by common
352 SNPs for metabolic syndrome traits. *PLoS Genet.* 2012;8:e1002637.
- 353 [13] Jermendy G, Horvath T, Littvay L, Steinbach R, Jermendy AL, Tarnoki AD, et al. Effect of
354 genetic and environmental influences on cardiometabolic risk factors: a twin study. *Cardiovasc*
355 *Diabetol.* 2011;10:96.
- 356 [14] Povel C, Boer J, Feskens E. Shared genetic variance between the features of the metabolic
357 syndrome: heritability studies. *Molecular Genetics and Metabolism.* 2011;104:666-9.
- 358 [15] Zhang S, Liu X, Yu Y, Hong X, Christoffel KK, Wang B, et al. Genetic and environmental
359 contributions to phenotypic components of metabolic syndrome: a population-based twin study.
360 *Obesity (Silver Spring).* 2009;17:1581-7.
- 361 [16] Klimentidis YC, Arora A, Newell M, Zhou J, Ordovas JM, Renquist BJ, et al. Phenotypic
362 and genetic characterization of lower LDL-C and increased type-2 diabetes risk in the UK
363 Biobank. *Diabetes.* 2020.
- 364 [17] Lotta LA, Sharp SJ, Burgess S, Perry JR, Stewart ID, Willems SM, et al. Association
365 between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2
366 diabetes: a meta-analysis. *Jama.* 2016;316:1383-91.

- 367 [18] Zhao W, Rasheed A, Tikkanen E, Lee JJ, Butterworth AS, Howson JMM, et al.
368 Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with
369 coronary heart disease. *Nat Genet.* 2017;49:1450-7.
- 370 [19] Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, et al. Exome-wide
371 association study of plasma lipids in > 300,000 individuals. *Nature genetics.* 2017;49:1758-66.
- 372 [20] Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk
373 of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet.*
374 2010;375:735-42.
- 375 [21] Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, et al. Statin use and
376 risk of developing diabetes: results from the Diabetes Prevention Program. *BMJ Open Diabetes
377 Research and Care.* 2017;5.
- 378 [22] Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident
379 diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
380 *JAMA.* 2011;305:2556-64.
- 381 [23] King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be
382 approved? Revised estimates of the impact of genetic support for drug mechanisms on the
383 probability of drug approval. *PLoS genetics.* 2019;15:e1008489.
- 384 [24] Plenge RM. Priority index for human genetics and drug discovery. *Nat Genet.*
385 2019;51:1073-5.
- 386 [25] Fang H, Consortium U-D, De Wolf H, Knezevic B, Burnham KL, Osgood J, et al. A
387 genetics-led approach defines the drug target landscape of 30 immune-related traits. *Nat Genet.*
388 2019;51:1082-91.

- 389 [26] Yaghootkar H, Lotta LA, Tyrrell J, Smit RA, Jones SE, Donnelly L, et al. Genetic evidence
390 for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart
391 disease. *Diabetes*. 2016;65:2448-60.
- 392 [27] Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank
393 resource with deep phenotyping and genomic data. *Nature*. 2018;562:203-9.
- 394 [28] Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide
395 association analysis identifies novel blood pressure loci and offers biological insights into
396 cardiovascular risk. *Nature genetics*. 2017;49:403.
- 397 [29] Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of
398 genetic correlations across human diseases and traits. *Nat Genet*. 2015;47:1236-41.
- 399 [30] Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery
400 and refinement of loci associated with lipid levels. *Nat Genet*. 2013;45:1274-83.
- 401 [31] Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, et al. New
402 genetic loci link adipose and insulin biology to body fat distribution. *Nature*. 2015;518:187-96.
- 403 [32] Hoffmann TJ, Ehret GB, Nandakumar P, Ranatunga D, Schaefer C, Kwok P-Y, et al.
404 Genome-wide association analyses using electronic health records identify new loci influencing
405 blood pressure variation. *Nature genetics*. 2017;49:54.
- 406 [33] Wheeler E, Leong A, Liu CT, Hivert MF, Strawbridge RJ, Podmore C, et al. Impact of
407 common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in
408 ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLoS Med*.
409 2017;14:e1002383.

- 410 [34] Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive
411 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat*
412 *Genet.* 2015;47:1121-30.
- 413 [35] Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al.
414 Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated
415 with stroke and stroke subtypes. *Nat Genet.* 2018;50:524-37.
- 416 [36] Loh PR, Kichaev G, Gazal S, Schoech AP, Price AL. Mixed-model association for biobank-
417 scale datasets. *Nat Genet.* 2018;50:906-8.
- 418 [37] Cichonska A, Rousu J, Marttinen P, Kangas AJ, Soininen P, Lehtimäki T, et al. metaCCA:
419 summary statistics-based multivariate meta-analysis of genome-wide association studies using
420 canonical correlation analysis. *Bioinformatics.* 2016;32:1981-9.
- 421 [38] Foley CN, Staley JR, Breen PG, Sun BB, Kirk PDW, Burgess S, et al. A fast and efficient
422 colocalization algorithm for identifying shared genetic risk factors across multiple traits.
423 *bioRxiv.* 2019:592238.
- 424 [39] Randall JC, Winkler TW, Kutalik Z, Berndt SI, Jackson AU, Monda KL, et al. Sex-stratified
425 genome-wide association studies including 270,000 individuals show sexual dimorphism in
426 genetic loci for anthropometric traits. *PLoS Genet.* 2013;9:e1003500.
- 427 [40] Liu CT, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, et al. Genome-wide
428 association of body fat distribution in African ancestry populations suggests new loci. *PLoS*
429 *Genet.* 2013;9:e1003681.
- 430 [41] Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, et al. Meta-
431 analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in
432 the genetic basis of fat distribution. *Nat Genet.* 2010;42:949-60.

- 433 [42] Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et
434 al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with
435 risk of coronary heart disease: A multivariable Mendelian randomisation analysis. *PLoS*
436 *medicine*. 2020;17:e1003062.
- 437 [43] Morris AP, Voight BF, Teslovich TM, Ferreira T, Segre AV, Steinthorsdottir V, et al.
438 Large-scale association analysis provides insights into the genetic architecture and
439 pathophysiology of type 2 diabetes. *Nature genetics*. 2012;44:981.
- 440 [44] Kanoni S, Masca NG, Stirrups KE, Varga TV, Warren HR, Scott RA, et al. Analysis with
441 the exome array identifies multiple new independent variants in lipid loci. *Hum Mol Genet*.
442 2016;25:4094-106.
- 443 [45] Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, Frossard P, et al. Genome-wide
444 association study in individuals of South Asian ancestry identifies six new type 2 diabetes
445 susceptibility loci. *Nat Genet*. 2011;43:984-9.
- 446 [46] Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic
447 Functional Enrichment to Improve GWAS Power. *Am J Hum Genet*. 2019;104:65-75.
- 448 [47] Zhu Z, Guo Y, Shi H, Liu C-L, Panganiban RA, Chung W, et al. Shared genetic and
449 experimental links between obesity-related traits and asthma subtypes in UK Biobank. *Journal of*
450 *Allergy and Clinical Immunology*. 2020;145:537-49.
- 451 [48] Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2
452 diabetes susceptibility loci identified through large-scale association analysis. *Nature genetics*.
453 2010;42:579.

- 454 [49] Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al.
455 Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*. 2010;466:707-
456 13.
- 457 [50] Ji Y, Yiorkas AM, Frau F, Mook-Kanamori D, Staiger H, Thomas EL, et al. Genome-wide
458 and abdominal MRI data provide evidence that a genetically determined favorable adiposity
459 phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart
460 disease, and hypertension. *Diabetes*. 2019;68:207-19.
- 461 [51] Small KS, Todorčević M, Civelek M, Moustafa JSE-S, Wang X, Simon MM, et al.
462 Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on
463 adipocyte size and body composition. *Nature genetics*. 2018;50:572-80.
- 464 [52] Loos RJ, Kilpeläinen TO. Genes that make you fat, but keep you healthy. *Journal of internal*
465 *medicine*. 2018;284:450-63.
- 466 [53] Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, et al. New loci for body fat
467 percentage reveal link between adiposity and cardiometabolic disease risk. *Nature*
468 *communications*. 2016;7:1-15.
- 469 [54] Kuk JL, Katzmarzyk PT, Nichaman MZ, Church TS, Blair SN, Ross R. Visceral fat is an
470 independent predictor of all-cause mortality in men. *Obesity*. 2006;14:336-41.
- 471 [55] Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjoström L. Distribution of adipose
472 tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the
473 population study of women in Gothenburg, Sweden. *Br Med J (Clin Res Ed)*. 1984;289:1257-61.
- 474 [56] Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue
475 and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. *Diabetologia*.
476 1976;12:563-71.

- 477 [57] Cassano PA, Segal MR, Vokonas PS, Weiss ST. Body fat distribution, blood pressure, and
478 hypertension. A prospective cohort study of men in the normative aging study. *Ann Epidemiol.*
479 1990;1:33-48.
- 480 [58] Seidell JC, Cigolini M, Deslypere JP, Charzewska J, Ellsinger BM, Cruz A. Body fat
481 distribution in relation to serum lipids and blood pressure in 38-year-old European men: the
482 European fat distribution study. *Atherosclerosis.* 1991;86:251-60.
- 483 [59] Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA, et al. Body fat
484 distribution and risk of non-insulin-dependent diabetes mellitus in women. *The Nurses' Health*
485 *Study. Am J Epidemiol.* 1997;145:614-9.
- 486 [60] Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and
487 weight gain as risk factors for clinical diabetes in men. *Diabetes care.* 1994;17:961-9.
- 488 [61] Nazare J-A, Smith JD, Borel A-L, Haffner SM, Balkau B, Ross R, et al. Ethnic influences
489 on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and
490 cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity
491 and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. *The American*
492 *journal of clinical nutrition.* 2012;96:714-26.
- 493 [62] Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, et al. Visceral adiposity and
494 its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk
495 factor levels. *The American journal of clinical nutrition.* 2008;88:1263-71.
- 496 [63] Tanko LB, Bagger YZ, Alexandersen P, Larsen PJ, Christiansen C. Peripheral adiposity
497 exhibits an independent dominant antiatherogenic effect in elderly women. *Circulation.*
498 2003;107:1626-31.

499 [64] Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of
500 Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes,
501 Coronary Disease, and Cardiovascular Risk Factors. *JAMA*. 2018;320:2553-63.

502 [65] Wu Y, Broadaway KA, Raulerson CK, Scott LJ, Pan C, Ko A, et al. Colocalization of
503 GWAS and eQTL signals at loci with multiple signals identifies additional candidate genes for
504 body fat distribution. *Human molecular genetics*. 2019;28:4161-72.

505 [66] Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random
506 allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease
507 mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian
508 randomization study. *J Am Coll Cardiol*. 2015;65:1552-61.

509 [67] Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association
510 Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2
511 Diabetes: A Meta-analysis. *Jama*. 2016;316:1383-91.

512

513 **Table 1.** SNPs with significant associations in initial UK Biobank GWAS

| | n | <i>GRB14-COBL1</i> rs13389219:C/T | | | <i>KLF14</i> rs201632637:CTTTTTT/C | | | <i>RGS19-OPRL1</i> rs8126001: C/T | | | <i>VEGFA-C6orf223</i> rs998584: C/A | | |
|------------------|---------|--------------------------------------|-------|----------|---------------------------------------|-------|----------|--------------------------------------|-------|---------|--|-------|----------|
| | | β | SE | p | β | SE | p | β | SE | p | β | SE | p |
| TG (mmol/L) | 356,574 | 0.037 | 0.002 | 7.7E-63 | 0.032 | 0.002 | 1.8E-50 | 0.017 | 0.002 | 2.6E-15 | -0.040 | 0.002 | 2.6E-76 |
| LDL-C (mmol/L) | 431,167 | 0.018 | 0.002 | 2.4E-21 | 0.018 | 0.002 | 6.9E-22 | 0.017 | 0.002 | 1.0E-18 | -0.017 | 0.002 | 1.3E-18 |
| HDL-C (mmol/L) | 397,721 | -0.028 | 0.002 | 1.8E-50 | -0.031 | 0.002 | 5.8E-63 | -0.012 | 0.002 | 7.1E-11 | 0.035 | 0.002 | 3.2E-80 |
| HbA1c (mmol/mol) | 417,018 | 0.012 | 0.002 | 2.5E-09 | 0.011 | 0.002 | 2.6E-08 | 0.012 | 0.002 | 1.4E-09 | -0.020 | 0.002 | 2.8E-26 |
| SBP (mmHg) | 453,413 | 0.016 | 0.002 | 3.4E-16 | 0.015 | 0.002 | 8.3E-14 | 0.018 | 0.002 | 7.1E-19 | -0.011 | 0.002 | 2.4E-08 |
| DBP (mmHg) | 453,413 | 0.015 | 0.002 | 1.7E-14 | 0.017 | 0.002 | 3.8E-17 | 0.012 | 0.002 | 3.7E-10 | -0.016 | 0.002 | 1.1E-16 |
| WHRadjBMI | 456,823 | 0.026 | 0.002 | 3.4E-64 | 0.012 | 0.001 | 1.7E-15 | 0.013 | 0.001 | 3.1E-17 | -0.037 | 0.001 | 5.0E-139 |
| metacca-p | | | | 5.4E-220 | | | 2.1E-149 | | | 1.0E-60 | | | 0.0E+00 |

514 Abbreviations: DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; TG:
515 triglycerides; WHRadjBMI: waist-to-hip ratio adjusted for BMI

Table 2. Published associations for significant SNPs in GWAS discovery

| | Sample size | <i>GRB14-COBL1</i> rs13389219:C/T | | | <i>KLF14</i> rs11765979:A/C | | | <i>RGS19-OPRL1</i> rs7271530: C/T | | | <i>VEGFA-C6orf223</i> rs998584: C/A | | |
|---------------|---------------------------|--------------------------------------|--------|----------|--------------------------------|--------|----------|--------------------------------------|--------|----------|--|--------|----------|
| | | beta | se | p | beta | se | p | beta | se | p | beta | se | p |
| TG (mg/dl) | n _{max} =177,782 | 0.0271 | 0.0034 | 2.60E-15 | 0.0247 | 0.0047 | 2.32E-07 | 0.009 | 0.0056 | 4.71E-02 | 0.0293 | 0.0037 | 3.42E-15 |
| LDL-C (mg/dl) | n _{max} =173,012 | 0.022 | 0.0037 | 9.89E-08 | 0.0111 | 0.0052 | 3.26E-02 | 0.0093 | 0.0064 | 2.31E-02 | 0.0005 | 0.004 | 0.9359 |
| HDL-C (mg/dl) | n _{max} =173,012 | -0.0226 | 0.0035 | 4.54E-10 | -0.0412 | 0.0048 | 3.11E-17 | -0.0101 | 0.0059 | 9.65E-02 | -0.026 | 0.0038 | 2.27E-11 |
| HbA1C (%) | n=123,665 | 0.0062 | 0.0018 | 4.28E-04 | 0.0033 | 0.0018 | 6.08E-02 | 0.0051 | 0.0019 | 6.21E-03 | -0.0083 | 0.0024 | 4.92E-04 |
| SBP (mmHg) | n=99,785 | 0.122 | NA | 0.031 | 0.0863 | NA | 0.11 | 0.199 | NA | 7.70E-03 | 0.085 | NA | 0.23 |
| DBP (mmHg) | n=99,785 | 0.0634 | NA | 0.085 | 0.0248 | NA | 0.48 | 0.142 | NA | 3.50E-03 | 0.0707 | NA | 0.12 |
| WHRadjBMI | n=694,649 | 0.027 | 0.0035 | 3.20E-15 | 0.0088 | 0.0043 | 0.041 | 0.012 | 0.0045 | 7.70E-03 | 0.043 | 0.0038 | 1.10E-29 |


516 Note: Nominally significant associations ($P < .05$) in bold, standard errors (SE) not available in the published summary statistics for blood pressure.

517 rs11765979 at *KLF14* was used as a proxy for rs201632637 ($r^2=0.94$, CEU)

518 Abbreviations: DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood

519 pressure; TG: triglycerides; HHRadjBMI: waist-to-hip ratio adjusted for BMI

520 **Figure 1:** Radar plot showing association p-values for all four loci identified in UK Biobank in A) both men and women, B) women
521 only, and C) men only.



522

523